187 related articles for article (PubMed ID: 33909515)
1. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
2. CD73: an emerging checkpoint for cancer immunotherapy.
Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
[TBL] [Abstract][Full Text] [Related]
3. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
4. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jeffrey JL; Lawson KV; Powers JP
J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396
[TBL] [Abstract][Full Text] [Related]
5. 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
Bhattarai S; Pippel J; Scaletti E; Idris R; Freundlieb M; Rolshoven G; Renn C; Lee SY; Abdelrahman A; Zimmermann H; El-Tayeb A; Müller CE; Sträter N
J Med Chem; 2020 Mar; 63(6):2941-2957. PubMed ID: 32045236
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
Sharif EU; Kalisiak J; Lawson KV; Miles DH; Newcomb E; Lindsey EA; Rosen BR; Debien LPP; Chen A; Zhao X; Young SW; Walker NP; Sträter N; Scaletti ER; Jin L; Xu G; Leleti MR; Powers JP
J Med Chem; 2021 Jan; 64(1):845-860. PubMed ID: 33399453
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.
Gong YP; Wan RZ; Liu ZP
Expert Opin Ther Pat; 2018 Feb; 28(2):167-171. PubMed ID: 29166791
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Substituted 5'-Aminoadenosine Derivatives and Evaluation of Their Inhibitory Potential toward CD73.
Ghoteimi R; Nguyen VT; Rahimova R; Grosjean F; Cros-Perrial E; Uttaro JP; Mathé C; Chaloin L; Jordheim LP; Peyrottes S
ChemMedChem; 2019 Aug; 14(15):1431-1443. PubMed ID: 31264794
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling.
Knapp K; Zebisch M; Pippel J; El-Tayeb A; Müller CE; Sträter N
Structure; 2012 Dec; 20(12):2161-73. PubMed ID: 23142347
[TBL] [Abstract][Full Text] [Related]
10. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
11. A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms.
Stefano JE; Lord DM; Zhou Y; Jaworski J; Hopke J; Travaline T; Zhang N; Wong K; Lennon A; He T; Bric-Furlong E; Cherrie C; Magnay T; Remy E; Brondyk W; Qiu H; Radošević K
J Biol Chem; 2020 Dec; 295(52):18379-18389. PubMed ID: 33122192
[TBL] [Abstract][Full Text] [Related]
12. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies.
Antonioli L; Novitskiy SV; Sachsenmeier KF; Fornai M; Blandizzi C; Haskó G
Drug Discov Today; 2017 Nov; 22(11):1686-1696. PubMed ID: 28676406
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.
Geoghegan JC; Diedrich G; Lu X; Rosenthal K; Sachsenmeier KF; Wu H; Dall'Acqua WF; Damschroder MM
MAbs; 2016; 8(3):454-67. PubMed ID: 26854859
[TBL] [Abstract][Full Text] [Related]
14. Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A
Varano F; Catarzi D; Vincenzi F; Pasquini S; Pelletier J; Lopes Rangel Fietto J; Espindola Gelsleichter N; Sarlandie M; Guilbaud A; Sévigny J; Varani K; Colotta V
Bioorg Med Chem Lett; 2020 May; 30(9):127067. PubMed ID: 32165041
[TBL] [Abstract][Full Text] [Related]
15. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
Kumar M; Lowery R; Kumar V
SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
[TBL] [Abstract][Full Text] [Related]
16. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.
Du X; Moore J; Blank BR; Eksterowicz J; Sutimantanapi D; Yuen N; Metzger T; Chan B; Huang T; Chen X; Chen Y; Duong F; Kong W; Chang JH; Sun J; Zavorotinskaya T; Ye Q; Junttila MR; Ndubaku C; Friedman LS; Fantin VR; Sun D
J Med Chem; 2020 Sep; 63(18):10433-10459. PubMed ID: 32865411
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer.
Zhou Q; Ding W; Qian Z; Zhu Q; Sun C; Yu Q; Tai Z; Xu K
Mol Pharm; 2021 Nov; 18(11):4015-4028. PubMed ID: 34648293
[TBL] [Abstract][Full Text] [Related]
18. CD73: a novel target for cancer immunotherapy.
Zhang B
Cancer Res; 2010 Aug; 70(16):6407-11. PubMed ID: 20682793
[TBL] [Abstract][Full Text] [Related]
19. Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
Wang Y; Wang C; Zhu Y; Zhang Y; Chen B; Wu Y; Yao J; Miao Z
Bioorg Med Chem Lett; 2021 Feb; 34():127758. PubMed ID: 33359608
[TBL] [Abstract][Full Text] [Related]
20. Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.
Rahimova R; Fontanel S; Lionne C; Jordheim LP; Peyrottes S; Chaloin L
PLoS Comput Biol; 2018 Jan; 14(1):e1005943. PubMed ID: 29377887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
